John B. Buse, MD, PhD: The GLP-1 receptor agonists are relatively recent drugs for the treatment of type 2 diabetes. They have very broad effects. There was a lot of interest in the possibility that they might reduce cardiovascular risk because they are associated with weight loss, modest reductions in blood pressure, and really outstanding glucose lowering.
Furthermore, in animal models and detailed in vitro studies, there are a variety of mechanisms in aerobiology that are impacted by these drugs, and as an example, it has been shown to have effects on plaque stability. And so, there was a lot of interest in the possibility that they may be associated with cardiovascular benefit. With the prior track record of drugs that had great evidence for the possibility of cardiovascular benefit not panning out, we were very interested in cardiovascular outcome studies.
The first cardiovascular outcome study conducted with a GLP-1 receptor agonist came out in 2016 and involved a GLP-1 receptor agonist called lixisenatide. Lixisenatide is an analog of exenatide, which was the first GLP-1 receptor agonist. Lixisenatide is administered once a day, but it doesn’t have a 24-hour duration of action. The study that was conducted, the ELIXA trial, involved patients who had recently survived a hospitalization for acute coronary syndrome, and they used a 4-point MACE endpoint: heart attack, stroke, cardiovascular death, or hospitalization for unstable angina. It’s a little bit different than the other cardiovascular outcome trials we’ve been talking about.
They showed no evidence of harm from lixisenatide with regards to cardiovascular outcomes, but also no evidence of benefit. And so, the community was a little bit disappointed, with the background of that hope, that there wasn’t greater benefit from lixisenatide.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Diabetes Risk Driven by Economic Disparity in Hispanic, Latino Communities
March 28th 2025Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors like education level significantly impact diabetes and hypertension rates, highlighting the need for targeted health interventions across diverse subgroups.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More